Public Origin-Market Prices and Global Access to Chinese-Origin Oncology Medicines: An Exploratory Multiple-Case Study

Affordable access to cancer medicines depends not only on clinical value but also on the pricing and reimbursement arrangements adopted as products expand across markets. We conducted an exploratory multiple-case study of four Chinese-origin oncology medicines—zanubrutinib, fruquintinib, tislelizumab, and efbemalenograstim alfa—to examine whether a low, publicly visible origin-market price could create international price-reference exposure. We compared reported public unit prices across approved markets, summarised monthly medicine acquisition costs from labelled dosing schedules, and triangulated approval timing with entry into the China National Reimbursement Drug List. China had the lowest observed public price for every medicine at market exchange rates; the observed country sets differed by medicine. Three medicines were first approved in China and expanded later to the United States and/or Europe, and all four entered the NRDL. The Chinese-origin product had a lower reported median monthly acquisition cost in three of four comparator pairs. These findings document a visible origin-market price anchor rather than a demonstrated causal effect on foreign prices, launch timing, or clinical value. For oncology pharmacy and health-system decision makers, price transparency and reimbursement design should support patient access while preserving the conditions for sustainable international availability of innovative cancer medicines.